The Prevalence of 30 HPV genotypes detected by EUROArray HPV in cervical samples among unvaccinated women from Vojvodina province, Serbia
Cite this dataset
Kovacevic, Gordana et al. (2021). The Prevalence of 30 HPV genotypes detected by EUROArray HPV in cervical samples among unvaccinated women from Vojvodina province, Serbia [Dataset]. Dryad. https://doi.org/10.5061/dryad.rxwdbrv7b
Abstract
This study evaluates the pre-vaccination prevalence of HPV infection in women from Vojvodina, Serbia, according to age and cytological status. A total of 1,495 women, ranging from 18 to 65 years of age, with different cytological results were enrolled. The HPV genotyping assay was performed using the EUROArray HPV test in order to detect thirty genitally relevant HPV subtypes. In our study, the most prevalent genotypeswere HPV 16, 31, 51, and 53. Among these, HPV 16 was consistently present in all cytological subgroups. Twelve HPV genotypes classified as carcinogenic to humans (Group 1) were detected in 77.8% of HSIL/ASCH and 55.0% of NILM with abnormal colposcopy findings. Six possible carcinogens - HRs (group 2B) were often found in women with normal cytology (14.8%) and mild abnormalities (ASCUS and LSIL), but with lower frequence in HSIL/ASCH lesions (7.1%). HPVs 6 and 11(Group 3) were not found in the cases of HSIL/ASCH. Unclassified HPV types were equally distributed in all cytology groups: 20.7%, 19.1%, 16.3% and 13% of NILM, ASCUS, LSIL and HSIL/ASCH, respectively. Our findings highlight that majority of abnormal Pap test results are caused by Group 1 HPVs among women from our region. Low frequency HPVs of group 2A/2B, especially HSIL/ASCH, supports the conclusion that individual genotypes require consideration of each type as an individual agent. We expect a positive impact of HPV vaccine in reducing HPV-associated cervical lesions among women from Vojvodina province, after establishing vaccination programs in our country.
Methods
This study was conducted within the ongoing project: “Significance of HPV DNA analysis in the prevention of cervical cancer” and the results outcome of the analysis conducted from 2016 to 2018. This was a cross-sectional study with convenience type of sampling. HPV DNA was generated from the laboratory analysis from the specimens provided by study participants.
Usage notes
Samples for HPV DNA analysis were collected using ThinPrep Pap (Hologic Inc.) or eNAT (Copan, Italy) specimen transport medium.
Funding
City of Novi Sad, City Administration for Health, Award: Project Numbers XII-51-46-3/2016, XII-51-46-51/2017, XII-51-52-7/2018
Merck Sharp & Dohme, D.O.O.*
City of Novi Sad, City Administration for Health, Award: Project Numbers XII-51-46-3/2016, XII-51-46-51/2017, XII-51-52-7/2018
Merck Sharp & Dohme, D.O.O.